Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
A retrospective analysis characterized actionable genomic alterations in patients with advanced cholangiocarcinoma (CCA). Results of this analysis were presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
In this analysis, next-generation sequencing (NGS) data from both circulating tumor and tissue were obtained from patients with advanced CCA. Tempus xT tissue biopsy assay and/or Tempus xF liquid biopsy assay were used to detect germline and/or somatic mutations, including single-nucleotide variants, specific insertion/deletions, amplifications, and gene fusions.
Of the 174 genomic results obtained, 113 were tissue-based NGS results and 61 were liquid-based NGS results. A total of 296 unique alterations were identified. Actionable genetic alterations were identified in 28.8% of the cases, including FGFR2 fusions (6.8%), IDH1/2 (8.4%), BRAF-V600E (2.5%), HER2 (3.0%), MET (0.7%), BRCA1/2/ATM (2%), PIK3CA (4.7%), and ERRFI1 (0.7%). Of these, actionable mutations were found in 33.1% in the ctDNA liquid biopsy cohort and 23.2% in the tissue biopsy cohort. FGFR2 fusion results did not correlate between ctDNA and tissue NGS samples, with FGFR2 fusions being detected in 11.3% of liquid biopsy samples and 3.4% of tissue-based samples.
These data support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Source: Kasi PM, Le AD, Barrett A. Comparative landscape of actionable somatic alterations in advanced cholangiocarcinoma from circulating tumor and tissue-based DNA profiling. J Clin Oncol. 2021;39(suppl_3):342-342.
To sign up for our newsletter or print publications, please enter your contact information below.
